TI:Studies on Vero Cell2derived Hemorrhagic Fever with Renal Syndrome Vaccine

AU:LI Minhong , ZHU Zhiyong , WENG Jingqing, et al

AD: Center f or Disease Cont rol and Prevention , Zhejiang Province , Hangz hou 310009 ,China

【Abstract】Objective Vero cell2derived HFRS purified vaccine researching and producing. Methods 　The vaccinal strains Z10 ( type Ⅰ) and Z37 ( type Ⅱ) of HFRS bivalent inactivated vaccine were adapted in vero cells and continuously porpagated. The Vero cell2derived HFRS purified vaccine were developed using the different passages of these 2 viral strains.Results 　The strains Z10 and Z37 were adapted to Vero cells and grew on cells with high titers only after one time passages. The viral titers reached and maintained stably between 6. 2526. 75 and 6. 5027. 00 logTCID50/ ml respectively after serial passages in Vero cells. The amounts of virus antigen and viral titers of Vero cell2derived HFRS inactivated vaccine made from different passages of these viral strains were much higher than the former. The RPHI titers of strains Z10 increased from negative for Cp1 to 1∶64 for Cp10 , and that of strains Z37 from 1∶2 for Cp1 to 1∶64 for Cp10 . The viral titers (logTCID50/ ml) of strains Z10 raised from 4. 25 for Cp1 to 6. 50 for Cp10 and that of strains Z37 from 6. 25 for Cp1 to 7. 50 for Cp10 . The viral titers and the amounts of virus antigen were up to the standand of biological products in China. Conclusion 　In the study on the HFRS purified vaccine in Vero cells ,the most important thing is the passage adaptability of vaccinal strain in Vero cells.

【Key words】　Hemorrhagic fever with renal syndrome ; Vero cells ; Vaccine ; Serial passages